var title_f23_3_23600="Lateral skull of elderly woman with Paget disease";
var content_f23_3_23600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral skull of an elderly woman with Paget disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral skull of an elderly woman with Paget disease. Note the thickened table of the skull, the areas of lytic mixed with sclerotic bone and the appearance of 'cotton wool spots' or circular densities of sclerotic bone so characteristic of PDB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Margaret Seton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23600=[""].join("\n");
var outline_f23_3_23600=null;
var title_f23_3_23601="Hollenhorst plaque retinal artery";
var content_f23_3_23601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hollenhorst plaque retinal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Digital Reference of Opthalmology, Edward S. Harkness Eye Institute, Columbia University, NY.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23601=[""].join("\n");
var outline_f23_3_23601=null;
var title_f23_3_23602="Robertsonian translocation";
var content_f23_3_23602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Robertsonian translocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a Robertsonian translocation in which the long arms of one chromosome 14 and one chromosome 21 are fused in the carrier parent (upper panel) is a cause of Down syndrome in the offspring. One of the three viable gametes will be normal, one will have a balanced rearrangement, and one will contain the fused chromosome [der(14;21)] as well as the unaffected chromosome 21. Normal fertilization of this gamete results in a fetus with trisomy 21. Other possible segregation products are gametes lacking a chromosome 21, gametes lacking a chromosome 14, and gametes with one chromosome 14 and a derivative chromosome der(14;21), all of which are not viable.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Iris Schrijver, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23602=[""].join("\n");
var outline_f23_3_23602=null;
var title_f23_3_23603="Patient information: Drug allergy (The Basics)";
var content_f23_3_23603=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87576\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"         Hives",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/4/3137\">",
"          Rash caused by drug allergy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/24/42370\">",
"         Patient information: Allergy skin testing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/38/12898\">",
"         Patient information: Stevens-Johnson syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/34/32290\">",
"         Patient information: Taking medicines when you're older (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/12/12483\">",
"         Patient information: What you should know about antibiotics (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/37/22098\">",
"         Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/14/41186\">",
"         Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/30/28134\">",
"         Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Drug allergy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H623760130\">",
"      <span class=\"h1\">",
"       What is a drug allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A drug allergy, also called drug hypersensitivity, is a bad reaction to a drug that happens when the body&rsquo;s immune system responds to a drug as if it were a dangerous invader and tries to fight it off. The job of the immune system is to fight off infection. Normally, it should not react to a drug as though it were an invader, but some drugs can cause that response in some people.",
"     </p>",
"     <p>",
"      The symptoms of a drug allergy can include a skin rash, itching, swelling, or&mdash;in severe cases&mdash;trouble breathing or a drop in blood pressure that can cause a person to pass out.",
"     </p>",
"     <p>",
"      A drug allergy is NOT the same as a drug side effect. Side effects are unintended or unwanted effects that drugs can cause. Side effects can affect anyone who is given enough of a drug. Drug allergies, on the other hand, affect only a small number of people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H623760145\">",
"      <span class=\"h1\">",
"       What are the symptoms of a drug allergy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a few different types of drug allergy, each with its own set of symptoms.",
"     </p>",
"     <p>",
"      One serious type of allergy is called an &ldquo;immediate&rdquo; allergy because it starts quickly after a drug is taken (usually within an hour or so). It usually happens with drugs that a person had taken before without any problem. Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hives, which are raised, red patches of skin that are usually very itchy (",
"        <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Itchy skin",
"       </li>",
"       <li>",
"        Flushing, which is when your skin turns red and feels hot",
"       </li>",
"       <li>",
"        Swelling of the face, hands, feet, or throat",
"       </li>",
"       <li>",
"        Throat tightness, hoarse voice, wheezing, or trouble breathing",
"       </li>",
"       <li>",
"        Nausea, vomiting, belly pain",
"       </li>",
"       <li>",
"        Feeling lightheaded",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      This type of allergy is serious because it can get worse if the medicine is continued. It can turn into a life-threatening whole-body allergic reaction, called anaphylaxis.",
"     </p>",
"     <p>",
"      Another type of drug allergy, called a &ldquo;delayed&rdquo; allergy, is much more common. This type is not very serious and usually causes a rash that begins after a few days of taking a drug. The rash often spreads over much of the skin (",
"      <a class=\"graphic graphic_picture graphicRef87350 \" href=\"UTD.htm?3/4/3137\">",
"       picture 2",
"      </a>",
"      ). Sometimes it is itchy, but sometimes not. This type of drug allergy does not involve swelling, trouble breathing, throat tightness, or the other symptoms listed above. This type of allergy doesn&rsquo;t usually get worse or affect anything besides the skin. (A rare but severe skin reaction to a drug, called Stevens Johnson syndrome, is discussed separately.) (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/38/12898?source=see_link\">",
"       \"Patient information: Stevens-Johnson syndrome (The Basics)\"",
"      </a>",
"      .)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H623760200\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what kind of reaction you have.",
"     </p>",
"     <p>",
"      Call 9-1-1 for an ambulance if you start a new medicine and develop any of the symptoms listed below:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wheezing or trouble breathing",
"       </li>",
"       <li>",
"        Chest tightness or pain",
"       </li>",
"       <li>",
"        Passing out or feeling as if you will pass out",
"       </li>",
"       <li>",
"        Swelling of your face, lips, tongue, or throat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call your doctor or nurse if you start a new medicine and develop any of the symptoms listed below:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hives (raised red welts on the skin that are usually very itchy)",
"       </li>",
"       <li>",
"        Feeling like you want to hurt or kill yourself",
"       </li>",
"       <li>",
"        Severe stomach ache or vomiting",
"       </li>",
"       <li>",
"        High fever",
"       </li>",
"       <li>",
"        Painful skin",
"       </li>",
"       <li>",
"        Skin blisters",
"       </li>",
"       <li>",
"        Pain and irritation of the pink, moist tissue that lines the eyes, mouth, vagina, and other organs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H623760215\">",
"      <span class=\"h1\">",
"       How is a drug allergy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a severe reaction to a drug you will be treated in a hospital. There your healthcare team will try to get your body back to normal. To do that, they might have to give you medicines to calm your allergic response. They might also need to give you oxygen to breathe through a mask, and fluids through a tube (called an &ldquo;IV&rdquo;) that goes into a vein.",
"     </p>",
"     <p>",
"      After your symptoms are managed, your doctor will explore what to do about the allergy. If possible, your doctor might try to switch you to a different drug that is less likely to cause the same reaction. If that is not possible, he or she might send you to an allergist to decide what to do next.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H623760230\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If your allergist suspects you have an immediate drug allergy, he or she might send you for allergy skin tests. The most common is called a skin prick test. For this test, the doctor puts a drop of the drug you might be allergic to on your skin and makes a tiny prick in your skin. He or she then watches your skin to see if it turns red and bumpy. This is to check if you have a true allergy.",
"     </p>",
"     <p>",
"      If you have a reaction that consists only of a rash (the type that is not serious), your allergist might want to do a &ldquo;drug challenge test.&rdquo; For this test, the allergist will have you take a small amount of the drug that caused the rash while he or she observes you. That way the doctor can find out if you will have the same reaction twice. Doctors usually do drug challenge tests only with medicines that are very useful, such as the antibiotic",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/2/39972?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . Amoxicillin is the best choice of antibiotic for many common infections, so it would be a problem if someone had to avoid it forever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H623760245\">",
"      <span class=\"h1\">",
"       Can a drug allergy be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you already know you have a drug allergy, you can reduce your chances of having problems again if you do the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tell all your doctors and nurse, and anyone who might prescribe medicines for you about your allergy. Medicines sometimes have more than 1 ingredient and go by more than 1 name, so it won&rsquo;t always be obvious if you are being prescribed the problem drug. Also, drugs are sometimes related to each other. If you are allergic to a specific drug, you might also be allergic to others that are related to it. If you tell your doctor or nurse about your allergy, he or she can try to avoid giving you any drugs that could cause problems.",
"       </li>",
"       <li>",
"        Always wear a medic alert bracelet or necklace explaining your drug allergy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H623760260\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=see_link\">",
"       Patient information: Allergy skin testing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/12/12483?source=see_link\">",
"       Patient information: What you should know about antibiotics (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/38/12898?source=see_link\">",
"       Patient information: Stevens-Johnson syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=see_link\">",
"       Patient information: Taking medicines when you're older (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/3/23603?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87576 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23603=[""].join("\n");
var outline_f23_3_23603=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760130\">",
"      What is a drug allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760145\">",
"      What are the symptoms of a drug allergy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760200\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760215\">",
"      How is a drug allergy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760230\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760245\">",
"      Can a drug allergy be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H623760260\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"      Hives",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/4/3137\">",
"       Rash caused by drug allergy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=related_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/38/12898?source=related_link\">",
"      Patient information: Stevens-Johnson syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/34/32290?source=related_link\">",
"      Patient information: Taking medicines when you're older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/12/12483?source=related_link\">",
"      Patient information: What you should know about antibiotics (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_3_23604="Choriocarcinoma ectopic preg";
var content_f23_3_23604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Choriocarcinoma in an ectopic pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal image of the right adnexa in a pregnant patient shows a heterogenous mass with cystic and solid components. This was a choriocarcinoma in an ectopic pregnancy, which is a distinctly unusual presentation of choriocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23604=[""].join("\n");
var outline_f23_3_23604=null;
var title_f23_3_23605="Arginine: Pediatric drug information";
var content_f23_3_23605=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Arginine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4980?source=see_link\">",
"    see \"Arginine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/56/35715?source=see_link\">",
"    see \"Arginine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      R-Gene&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent, Growth Hormone Function",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Metabolic Alkalosis Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urea Cycle Disorder (UCD) Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11432602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of urea cycle disorders (in combination with sodium phenylacetate and sodium benzoate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS) disorders or pending definitive diagnosis: 600 mg/kg as a loading dose followed by 600 mg/kg/day as a continuous infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) disorder: 200 mg/kg as a loading dose followed by 200 mg/kg/day as a continuous infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent hyperammonemic crisis in patients with urea cycle disorders:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ASL or ASS: 0.6 g/kg or 12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     loading dose followed by 0.6 g/kg/day or 12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CPS or OTC: 0.2 g/kg or 4 g/m",
"     <sup>",
"      2",
"     </sup>",
"     loading dose followed by 0.2 g/kg/day or 4 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V., Oral: Necrotizing enterocolitis (NEC), prevention: 261 mg/kg/day added to enteral or parenteral nutrition beginning on day of life 2-5 and continued for 28 consecutive days. In a single-center, prospective, double-blind, randomized, placebo-controlled trial of 75 neonates (GA: &lt;32 weeks; birth weight: &lt;1250 g) in Canada, arginine supplementation decreased the NEC incidence when compared to placebo (6.7% vs 27%) (Amin, 2002; Shah, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     The only commercial product available in the U.S. is arginine HCl injection and it is not known whether the hydrochloride salt was used in the Canadian study. Increased administration of HCl in this patient population could result in hyperchloremic metabolic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4980?source=see_link\">",
"      see \"Arginine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: (",
"     <b>",
"      Note:",
"     </b>",
"     Each 1 g provides 4.75 mEq  chloride)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Growth hormone reserve test:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.5 g/kg over 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 30 g (300 mL) over 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of urea cycle disorders: Infants, Children, and Adults (in combination with sodium phenylacetate and sodium benzoate):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS) disorders or pending definitive diagnosis: 600 mg/kg as a loading dose followed by 600 mg/kg/day as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) disorder: 200 mg/kg as a loading dose followed by 200 mg/kg/day as a continuous infusion. A single case using 60 mg/kg/hour for 12 hours has been reported (Kodama, 1996).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hyperammonemic crisis in patients with urea cycle disorders: Infants, Children, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ASL or ASS: 0.6 g/kg or 12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     loading dose followed by 0.6 g/kg/day or 12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CPS or OTC: 0.2 g/kg or 4 g/m",
"     <sup>",
"      2",
"     </sup>",
"     loading dose followed by 0.2 g/kg/day or 4 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolic alkalosis: Infants, Children, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Arginine hydrochloride is an alternative treatment for uncompensated metabolic alkalosis after sodium chloride and potassium chloride supplementation have been optimized; it should not be used as initial therapy for chloride supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Arginine hydrochloride dose (mEq) = 0.5 x weight (kg) x [HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     - 24] where HCO",
"     <sub>",
"      3",
"     </sub>",
"     <sup>",
"      -",
"     </sup>",
"     = the patient's serum bicarbonate concentration in mEq/L (Adrogu&eacute;, 1998; Martin, 1982); give",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     to",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of calculated dose and re-evaluate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     To correct hypochloremia: Infants, Children, and Adults: Arginine hydrochloride dose (mEq) = 0.2 x weight (kg) x [103 - Cl",
"     <sup>",
"      -",
"     </sup>",
"     ] where Cl",
"     <sup>",
"      -",
"     </sup>",
"     = the patient's serum chloride concentration in mEq/L (Martin, 1982); give",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     to",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of calculated dose and re-evaluate",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     R-Gene&reg; 10: 10% [100 mg/mL] (300 mL) [contains chloride 0.475 mEq/mL; 950 mOsm/L]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: May be infused without further dilution (however, very irritating to tissues, dilution is recommended); administration through a central line is recommended; maximum rate of I.V. infusion: 1 g/kg/hour (4.75 mEq/kg/hour) (maximum dose: 60 g/hour = 285 mEq over 1 hour); infuse loading doses for urea cycle disorders over 90 minutes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pituitary function test (stimulant for the release of growth hormone); management of severe, uncompensated, metabolic alkalosis (pH &ge;7.55)",
"     <b>",
"      after",
"     </b>",
"     optimizing therapy with sodium or potassium chloride supplements; treatment agent for urea cycle disorders (FDA approved in children and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7905819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Food and Drug Administration (FDA) has identified several cases of fatal arginine overdose in children and has recommended that healthcare professionals always recheck dosing calculations prior to administration of arginine. Doses used in children should not exceed usual adult doses.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing (with rapid I.V. infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Venous irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, cerebral edema, hematuria, hyperkalemia, hypersensitivity reaction, injection site reaction, skin burn/necrosis (due to extravasation), lethargy, loss of consciousness, perioral tingling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to arginine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arginine hydrochloride is metabolized to nitrogen-containing products for excretion; the temporary effect of a high nitrogen load on the kidneys should be evaluated; accumulation of excess arginine may result in an overproduction of nitric oxide, leading to vasodilation and hypotension; each 1 mEq chloride delivers 1 mEq hydrogen; monitor acid base balance closely, particularly in neonates",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use extreme caution when administering to neonates and children as overdosage has resulted in hyperchloremic metabolic acidosis, cerebral edema, or possibly death. Use with caution in renal or hepatic failure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, the manufacturer does not recommend use of arginine during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acid-base status (arterial or capillary blood gases), serum electrolytes, BUN, glucose, plasma growth hormone concentrations (when evaluating growth hormone reserve), plasma ammonia and amino acids (when treating urea cycle disorders)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If intact pituitary function, human growth hormone levels should rise after arginine administration to 10-30 ng/mL (control range: 0-6 ng/mL)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates pituitary release of growth hormone and prolactin and pancreatic release of glucagon and insulin; patients with impaired pituitary function have lower or no increase in plasma concentrations of growth hormone after administration of arginine. Arginine hydrochloride has been used for treatment of hypochloremic metabolic alkalosis due to its high chloride content. Arginine becomes an essential amino acid in ASL deficiency due to a decrease in the conversion of argininosuccinate to arginine; in other urea cycle disorders, exogenous arginine is used to produce increased serum concentrations and to prevent the breakdown of endogenous protein. Arginine is a precursor to nitric oxide and can produce vasodilation and inhibition of platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 0.7-1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :. 33-100 L/kg",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When treating urea cycle disorders, sodium bicarbonate use may be necessary to neutralize the acidifying effects of arginine HCl.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adrogu&eacute; HJ and Madias NE, \"Management of Life-Threatening Acid-Base Disorders. Second of Two Parts,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(2):107-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/9420343/pubmed\" id=\"9420343\" target=\"_blank\">",
"        9420343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amin HJ, Zamora SA, McMillan DD, et al, \"Arginine Supplementation Prevents Necrotizing Enterocolitis in the Premature Infant,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 140(4):425-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/12006956/pubmed\" id=\"12006956\" target=\"_blank\">",
"        12006956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):S46-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/11148549/pubmed\" id=\"11148549\" target=\"_blank\">",
"        11148549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bode-B&ouml;ger SM, B&ouml;ger RH, Galland A, et al, \"L-Arginine-Induced Vasodilation in Healthy Humans: Pharmacokinetic-Pharmacodynamic Relationship,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1998, 46(5):489-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/9833603/pubmed\" id=\"9833603\" target=\"_blank\">",
"        9833603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bushinsky DA and Gennari FJ, &ldquo;Life-Threatening Hyperkalemia Induced by Arginine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1978, 89(5 Pt 1):632-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/717931 /pubmed\" id=\"717931 \" target=\"_blank\">",
"        717931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kodama H, Mori Y, Kubota K, et al, \"Intravenous Arginine Dramatically Improved Hyperammonemia in a Patient With Late-Onset Ornithine Transcarbamylase Deficiency,\"",
"      <i>",
"       Tohoku J Exp Med",
"      </i>",
"      , 1996, 180(1):83-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/8933675/pubmed\" id=\"8933675\" target=\"_blank\">",
"        8933675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin WJ and Matzke GR, \"Treating Severe Metabolic Alkalosis,\"",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1982, 1(1):42-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/6764161/pubmed\" id=\"6764161\" target=\"_blank\">",
"        6764161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah P and Shah V, \"Arginine Supplementation for Prevention of Necrotising Enterocolitis in Preterm Infants,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2007, (3):CD004339.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/17636753/pubmed\" id=\"17636753\" target=\"_blank\">",
"        17636753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Summar M, &ldquo;Current Strategies for the Management of Neonatal Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):S30-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23605/abstract-text/11148547/pubmed\" id=\"11148547\" target=\"_blank\">",
"        11148547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12797 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23605=[""].join("\n");
var outline_f23_3_23605=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136608\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056560\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432602\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056554\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136592\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136578\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056564\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056563\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7905819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136626\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056567\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056553\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056552\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298769\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136586\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136588\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136600\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056559\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056562\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056551\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056566\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056568\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4980?source=related_link\">",
"      Arginine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/56/35715?source=related_link\">",
"      Arginine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_3_23606="Seborrehic keratosis - pigmented";
var content_f23_3_23606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A brown plaque with a \"stuck-on\" appearance is present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23606=[""].join("\n");
var outline_f23_3_23606=null;
var title_f23_3_23607="Erythromycin and sulfisoxazole: Drug information";
var content_f23_3_23607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin and sulfisoxazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11031?source=see_link\">",
"    see \"Erythromycin and sulfisoxazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      E.S.P.&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Macrolide;",
"     </li>",
"     <li>",
"      Antibiotic, Macrolide Combination;",
"     </li>",
"     <li>",
"      Antibiotic, Sulfonamide Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F166756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11031?source=see_link\">",
"      see \"Erythromycin and sulfisoxazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Otitis media:",
"     </b>",
"     Oral: Infants &ge;2 months and Children: Erythromycin 50 mg/kg/day and sulfisoxazole 150 mg/kg/day in divided doses every 6-8 hours for 10 days; maximum: Erythromycin 2 g/day or sulfisoxazole 6 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F166751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15837926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral suspension: Erythromycin ethylsuccinate 200 mg and sulfisoxazole acetyl 600 mg per 5 mL (100 mL, 150 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     E.S.P.&reg;: Erythromycin ethylsuccinate 200 mg and sulfisoxazole acetyl 600 mg per 5 mL (100 mL, 150 mL, 200 mL) [cheri beri flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15665038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals. Shake well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of otitis media caused by susceptible strains of",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pediazole&reg; may be confused with Pediapred&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Adverse events specific to this combination have not been identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Allergic myocarditis, arteritis, cyanosis, edema (including periorbital), flushing, intracranial hypertension, palpitations, periarteritis nodosa, syncope, tachycardia, torsade de pointes, vasculitis, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, depression, disorientation, dizziness, drowsiness, fatigue, fever, hallucinations, headache, insomnia, psychosis, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, erythema multiforme, exfoliative dermatitis, photosensitivity, pruritus, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter (rare), hypoglycemia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, flatulence, gastrointestinal hemorrhage, glossitis, hypertrophic pyloric stenosis, melena, nausea, oral candidiasis, pancreatitis, pseudomembranous colitis, salivary gland swelling, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, clotting disorders (including hypoprothrombinemia, hypofibrinogenemia, sulfhemoglobinemia, methemoglobinemia), eosinophilia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (including hepatitis, hepatic necrosis, and cholestatic jaundice), liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuritis, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss (reversible), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, blood urea nitrogen increased, crystalluria, diuresis (rare), hematuria, nephritis, serum creatinine increased, toxic nephrosis (with oliguria and anuria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonitis, pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions, serum sickness, systemic lupus erythematosus (SLE)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin, sulfonamides, or any component of the formulation; pregnant women at term; nursing mothers of infants &lt;2 months of age; infants &lt;2 months of age (sulfas compete with bilirubin for binding sites)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Macrolides have been associated with rare QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia, and other blood dyscrasias have occurred with sulfonamides; discontinue use at first sign of rash or signs of serious adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred with sulfonamides; discontinue use at first sign of rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred with sulfonamides; discontinue use at first sign of rash or signs of serious adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). In patients with allergy to one of these compounds, a risk of cross-reaction exists; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma/allergies: Use with caution in patients with allergies or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with pre-existing liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been observed with erythromycin. Discontinue if symptoms of malaise, nausea, vomiting, abdominal colic, and fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Erythromycin has been associated with aggravation of weakness associated with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Erythromycin (Systemic) may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May diminish the therapeutic effect of Erythromycin (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Erythromycin (Systemic) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Erythromycin (Systemic) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Erythromycin (Systemic) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary artery hypertension, concurrent use with erythromycin is not recommended.  When used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Erythromycin (Systemic) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Erythromycin (Systemic) may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Erythromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Erythromycin (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit dose of vardenafil film-coated tablets (Levitra)  to 5 mg per 24 hours with concomitant use of erythromycin. Concomitant use of vardenafil orally disintegrating tablets (Staxyn) with erythromycin is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: Erythromycin (Systemic) may decrease the serum concentration of Zafirlukast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8500881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination; therefore, the manufacturer classifies erythromycin/sulfisoxazole as pregnancy category C. Erythromycin and sulfisoxazole cross the placenta. Sulfisoxazole is contraindicated in late pregnancy because sulfonamides may cause kernicterus in the newborn. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8506124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Erythromycin and sulfisoxazole are both transferred to breast milk. Per the manufacturer, sulfisoxazole is contraindicated in mothers nursing infants &lt;2 months of age because sulfonamides cross into milk and may cause kernicterus in the newborn. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (E.S.P. Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-600 mg/5 mL (150 mL): $41.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Erythromycin-Sulfisoxazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-600 mg/5 mL (150 mL): $23.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, periodic liver function test, urinalysis, renal function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bioquin (CN);",
"     </li>",
"     <li>",
"      Erisul (CO);",
"     </li>",
"     <li>",
"      Pediazole (AE, BH, CN, CY, EC, EG, FR, GR, IL, IQ, IR, JO, KW, LB, LY, MX, MY, OM, PE, PH, PK, QA, SA, SY, TW, VE, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Erythromycin inhibits bacterial protein synthesis; sulfisoxazole competitively inhibits bacterial synthesis of folic acid from para-aminobenzoic acid",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfisoxazole (Also see Erythromycin monograph)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 85% (primarily to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (97%; 52% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23607/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez WJ, Schwartz RH, Sait T, et al, &ldquo;Erythromycin-Sulfisoxazole vs Amoxicillin in the Treatment of Acute Otitis Media in Children,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1985, 139(8):766-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23607/abstract-text/3895889/pubmed\" id=\"3895889\" target=\"_blank\">",
"        3895889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tartaglione TA, &ldquo;Therapeutic Options for the Management and Prevention of",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Infection in Patients With the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1996, 16(2):171-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/3/23607/abstract-text/8820462/pubmed\" id=\"8820462\" target=\"_blank\">",
"        8820462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9419 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-201.248.109.99-10E284DFB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23607=[""].join("\n");
var outline_f23_3_23607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166745\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166746\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166761\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166756\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166751\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837926\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166734\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166718\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15665038\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166736\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166769\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166759\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166739\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166722\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166757\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166727\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166730\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8500881\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166753\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8506124\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989364\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166732\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166742\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166721\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166738\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9419\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9419|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11031?source=related_link\">",
"      Erythromycin and sulfisoxazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_3_23608="Pathogenesis of psoriatic arthritis";
var content_f23_3_23608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of psoriatic arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Dafna D Gladman, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Christopher Ritchlin, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23608/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/3/23608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise causes of psoriasis and psoriatic arthritis (PsA) have not been identified. It seems likely, however, that genetic, immunologic, and environmental factors all contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also seems reasonable to assume that the skin and joint diseases have a similar pathogenesis although the activity of these manifestations does not always change in parallel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis has long been known to occur in families. The possible role of genetic factors is illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 40 percent of patients with psoriasis or PsA have a family history of these disorders in first degree relatives [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family studies in PsA have demonstrated that the disease is 55 times more likely to occur among first degree relatives than among unrelated controls [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/5\">",
"       5",
"      </a>",
"      ]. A significantly increased risk of PsA among first degree relatives of patients with PsA has also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/7\">",
"       7",
"      </a>",
"      ]. The concordance rate for PsA is much higher than that for psoriasis (30 versus 7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is greater concordance for psoriasis among monozygotic twins than among dizygotic twins [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HLA antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery of the major histocompatibility complex on chromosome six permitted further study of genetic factors in PsA. A number of associations have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The human leukocyte antigens (HLA)-B13, HLA-B17, HLA-B57, and HLA-Cw*0602 occur with increased frequency in patients with PsA when compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/1,2,9\">",
"       1,2,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The following HLA alleles were significantly associated with PsA compared with psoriasis in a multivariate regression analysis that compared 712 PsA patients with 335 psoriasis patients and 713 healthy controls: B*8, B*27, B*38, and C*06. Haplotypes independently associated with PsA compared with psoriasis included HLA-B*18, HLA-C*07, HLA-B*27, HLA-B38, and HLA-B*8. The highest positive predictive value was noted with HLA-B27 (assuming a 30 percent prevalence of PsA in patients with psoriasis, the PPV = 0.64) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with PsA, when compared with those with uncomplicated psoriasis, show an increased frequency of the HLA antigens B7 and B27 and a lower frequency of HLA-DR7 and HLA-Cw7 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/2\">",
"       2",
"      </a>",
"      ]. However, the frequency of HLA-B27 in PsA is not as high as it is in ankylosing spondylitis or in reactive arthritis, and a number of patients with psoriasis and spondyloarthropathy are HLA-B27 negative. In addition, many patients with PsA and HLA-B27 do not have a spinal manifestation.",
"     </li>",
"     <li>",
"      Several, but not all, studies have suggested an association between PsA and HLA-DR4, an antigen that has been shown to be associated with rheumatoid arthritis. However, this association can be demonstrated only in those patients with PsA who have a polyarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The HLA-DRB1*04 alleles in patients with PsA differ from those in patients with rheumatoid arthritis (RA). The HLA-DRB1*0401 allele is present less frequently among HLA-DRB1*04 positive patients with PsA than among those with RA, whereas HLA-DRB1*0402 is more frequent in those with PsA than in those with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/11\">",
"       11",
"      </a>",
"      ]. The prevalence of one or more of the ensemble of HLA-DRB1 alleles associated with RA, collectively referred to as encoding the &ldquo;shared epitope&rdquo; (SE), was not significantly greater in patients PsA than in healthy controls, but the presence of one of these SE alleles was increased in those with erosive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link&amp;anchor=H3#H3\">",
"       \"HLA and other susceptibility genes in rheumatoid arthritis\", section on 'Individual alleles and the shared epitope'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HLA-B27 antigen in the presence of HLA-DR7, HLA-DQ3 in the absence of HLA-DR7, and HLA-B39 are predictors for disease progression, whereas HLA-B22 is protective [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The PSORS1 gene, reported to be HLA-Cw*06:02, is the strongest susceptibility region for psoriasis. In a study of 909 PsA patients, TNF*-857T, a gene that increases transcription of tumor necrosis factor (TNF), is a risk allele for PsA independent of PSORS1 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a comparison of PsA cases with psoriasis patients and no musculoskeletal disease as determined by a rheumatologist, the frequency of HLA-C*0602 was significantly lower in PsA. HLA-C*06 was associated with a longer interval between onset of skin and joint disease, while B*27 alleles were significantly increased in frequency in PsA and were associated with a short interval between time of onset of skin and joint disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact mechanism of the association between HLA antigens and PsA is not clear. These antigens are thought to be important in antigen presentation and may, therefore, have a pathogenetic role. Alternatively, the HLA antigens may be in linkage disequilibrium with a disease susceptibility gene which may reside at or near the HLA locus.",
"   </p>",
"   <p>",
"    It has also been suggested that certain immunoglobulin genes may be associated with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, a gene for psoriasis has been identified on chromosome 17 in some families with familial psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunoglobulin-like receptors on natural killer cells (KIR gene products) interact with HLA class I molecules. Different KIR polymorphisms have opposite effects; carriage of an activating type allele (KIR2DS2 or KIR2DS1) is associated with an increased risk of PsA, but only in those who lacked an appropriate HLA class I ligand for an inhibitory KIR (ie, KIR2DL1 or",
"    <span class=\"nowrap\">",
"     KIR2DL2/3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/18\">",
"     18",
"    </a>",
"    ]. Moreover, there appears to be a &ldquo;dose response&rdquo; based upon the presence of the appropriate HLA-C ligand in association with the presence of activating KIR. Individuals who have KIR2DS1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    KIR2DS2 and who are Cw group homozygous are at most risk, whereas those who lack KIR2DS1 and KIR2DS2 and who are Cw group heterozygous are least susceptible to PsA.",
"   </p>",
"   <p>",
"    These HLA associated genetic factors have been shown to be important determinants of prognosis in PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/19\">",
"     19",
"    </a>",
"    ]. The HLA antigens B39, B27, and DQw3 are associated with disease progression, defined on the basis of an increase in clinical deformities. Furthermore, they may be more important prognostically than certain clinical features at presentation, such as the number of affected joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genome-wide scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;In psoriasis, linkages with loci on chromosomes 1p, 3q, 4q, 6p, 10q, 16q, 17q, 19p, and 20p have been reported in whole genome scans, with the strongest evidence for linkage on chromosome 6p, 10q, 16q, and 17q [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/5,20-22\">",
"     5,20-22",
"    </a>",
"    ]. A non-HLA gene was detected within the major histocompatibility complex (MHC) in psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/23\">",
"     23",
"    </a>",
"    ]. A segment of chromosome six telomeric to the HLA-C locus has been identified by two groups of investigators as closely associated with psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It remains unclear whether the same segment is relevant in PsA. A genome-wide association study (GWAS) in psoriasis has confirmed associations with HLA-C and also identified genes involved in interleukin (IL)-23 signaling (IL-23A, IL-23R, IL-12B), as well as two genes that regulate NF-&kappa;B, TNIP1, and TNFAIP3 and two genes involved in the modulation of TH2 immune responses IL-4 and IL-13. Moreover, HLA-C, IL-12B, and IL-23R were more significantly associated with psoriasis than PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/26\">",
"     26",
"    </a>",
"    ]. TNFAIP3 is thought to limit NF-&kappa;B-mediated immune responses, and two single REL nucleotide polymorphisms in this gene were associated with the response to anti-TNF agents in psoriasis and PsA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/27\">",
"     27",
"    </a>",
"    ]. A meta-analysis of GWAS studies on psoriasis, stratified for PsA, found an association of PsA with c-Rel, a member of the",
"    <span class=\"nowrap\">",
"     Rel/NF-&kappa;B",
"    </span>",
"    family [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genome-wide scan in 100 patients from 39 families with PsA in Iceland identified linkage to a site on chromosome 16q [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/29\">",
"     29",
"    </a>",
"    ]. Further analysis suggested that this genetic locus may be subject to imprinting, an epigenetic phenomenon in which only one of two homologous parenteral genes is active. In the case of PsA, the data suggest that inheritance of an allele from the father is more strongly associated with an increased risk of PsA in the children than is maternal inheritance of the same allele.",
"   </p>",
"   <p>",
"    A German genome-wide association study (GWAS) in psoriasis identified TRAF3IP2 on 6q21 to be associated with psoriasis. A stratified analysis confirmed its association with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/30\">",
"     30",
"    </a>",
"    ]. A meta-analysis of the two GWAS studies in psoriasis, which also included patients with PsA, identified three further susceptibility loci, including NOS2 (rs4795067), FBXL19 (rs10782001), and one near PSMA6-NFKBIA (rs12586317) for both psoriasis and PsA. The meta-analysis also replicated an association signal near RNF114 (rs495337). A dedicated GWAS in PsA is underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Candidate genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of individual genes in PsA have investigated candidates for disease association, including a number of candidates on chromosome 6p. The following findings have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased prevalence of variants of the CARD15 gene (also termed NOD2 or IBD1) on chromosome 16q noted in one study in North America [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/31\">",
"       31",
"      </a>",
"      ], but not in Italian, German, or United Kingdom cohorts [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. This gene is also implicated in the pathogenesis of Crohn&rsquo;s disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link&amp;anchor=H8#H8\">",
"       \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\", section on 'Genetic susceptibility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A unique gain of function mutation in caspase recruitment domain family, member CARD14, segregated with psoriasis which resulted in the upregulation of nuclear factor kappa B (NF-&kappa;B) and of a subset of psoriasis-associated genes in keratinocytes. The role of this mutation in PsA is unknown [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deletion of the late cornified envelope gene (LCE3C-LCE3B) variant was reported to be a susceptibility factor for PsA in Spanish and Italian populations (OR 1.35) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An association of PsA risk with tumor necrosis factor (TNF)-alpha promoter polymorphisms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/37,38\">",
"       37,38",
"      </a>",
"      ], of progressive erosive disease with TNF-alpha polymorphisms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/39\">",
"       39",
"      </a>",
"      ], and of an earlier age of onset with TNF-alpha and TNF-beta polymorphisms [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/39\">",
"       39",
"      </a>",
"      ]. The polymorphisms were different in each of the associations.",
"     </li>",
"     <li>",
"      A significant increase in the TNFa6c1d3 haplotype, which was independent of HLA class I alleles among patients with PsA but not with uncomplicated psoriasis and which was associated with a significant decrease in TNF-alpha production [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A class I MHC chain related gene A (MICA) associated with PsA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/41\">",
"       41",
"      </a>",
"      ] that was the only allele with a positive association in a Jewish population [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An association between Seek1, a potential susceptibility gene for psoriasis and PsA on chromosome 6p, in Newfoundland Canadians (a founder population) but not in residents of Ontario (a mixed population), which was likely due to linkage disequilibrium with HLA-Cw*0602 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A moderately strong correlation between the presence of the R620W allele of the lymphoid protein tyrosine phosphatase gene (PTPN22) and PsA in the Ontario population noted above but not in Newfoundlanders [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An association with at least two loci in the interleukin (IL)-1 family gene cluster on chromosome two [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An association with IL-23 receptor and IL-12-beta polymorphisms in PsA [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. However, both loci may be primarily associated with psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lack of association with PsA of another potential gene, RUNX1, thought to be related to psoriasis and arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Studies from two different centers identified associations between PsA and IL-13 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. Both studies showed that the association was with PsA and not with cutaneous psoriasis. An interaction between smoking and the IL-13 polymorphism was noted in one of the studies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible role for immunologic mechanisms is suggested by the inflammatory response in the psoriatic skin lesions and by the synovial lesions, which are, at times, indistinguishable from rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence suggests that the early phase of PsA is mediated primarily by tissue-specific factors and by innate immune mechanisms, whereas psoriasis is driven by both adaptive and innate immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/54\">",
"     54",
"    </a>",
"    ]. In established PsA, however, a number of immunologic abnormalities have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/55\">",
"     55",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated plasma levels of immunoglobulins and antinuclear antibodies have been identified, particularly directed against stratum corneum antigens.",
"     </li>",
"     <li>",
"      T cells express HLA-DR molecules and receptors for interleukin (IL)-2, as well as a variety of adhesion molecules, and secrete proinflammatory cytokines, especially IL-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibroblasts from the skin and synovium show enhanced proliferative activity and the capability to secrete increased amounts of IL-1-beta, IL-6, and platelet-derived growth factors.",
"     </li>",
"     <li>",
"      The pattern of proinflammatory cytokines seen in the synovium and in synovial fluid is similar to that seen in rheumatoid arthritis, with elevated levels of TNF-alpha, IL-1, IL-6, and IL-8, as well as upregulated levels of serum IL-10, IL-13, interferon (IFN)-alpha, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor, CCL4, and CCL11 and reduced levels of granulocyte-colony stimulating factor [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/56-58\">",
"       56-58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Synovial samples from patients with PsA produced more of some cytokines (TNF-alpha, IL-1B, IL-2, IL-10, and interferon gamma) and less of others (IL-4 and IL-5) than explants from patients with rheumatoid arthritis, suggesting that these two disorders may result from a different underlying mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/59\">",
"       59",
"      </a>",
"      ]. Moreover, the limited synovial lining layer hyperplasia, marked vascularity, influx of polymorphonuclear leukocytes (PMN), and lack of intracellular citrullinated proteins and MHC-C pg 39 peptide complexes are features common to PsA and the other spondyloarthropathies but not to RA synovium [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A role for T cells in the development of psoriatic skin lesions is suggested by a model in which uninvolved skin from patients with psoriasis is grafted onto mice with severe combined immunodeficiency (SCID mice); typical psoriatic lesions developed if the injected T cells were enriched for CD4 positive T cells but not if they were predominantly CD8 positive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activated T cells have generally been found in the affected tissues (both skin and joints) in patients with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/55\">",
"     55",
"    </a>",
"    ]. The T cells in synovial fluid are predominantly CD8 positive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Several studies have shown that cytokines secreted from activated T cells and from other mononuclear proinflammatory cells induce proliferation and activation of synovial and epidermal fibroblasts. It is unclear whether the activated T cells are the cause of the arthritis or are the result of unidentified factors. Studies have found Th17 cells in the psoriatic joint and synovial fluid along with IL-17 expressing mast cells in synovium. Despite these findings, the importance of the Th17 immune response in the pathogenesis of psoriatic joint inflammation is not well-understood [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is proposed that the direct activation of T cells bearing NK receptors for MHC class I triggers psoriasis. NK cell activity in the peripheral blood was shown to be lower than in the synovium in patients with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/66\">",
"     66",
"    </a>",
"    ]. NK cells which have been detected in psoriatic plaques also carry the interleukin (IL)-18 receptor. IL-18 is overexpressed in psoriatic lesional skin compared with human skin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/67\">",
"     67",
"    </a>",
"    ] and is elevated in patients with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/68\">",
"     68",
"    </a>",
"    ]. These findings further support the role of NK cells and KIR receptors in the pathogenesis of PsA.",
"   </p>",
"   <p>",
"    Increased numbers of osteoclast precursors have been observed in the peripheral blood of those with erosive PsA when compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/69\">",
"     69",
"    </a>",
"    ]. Cultured peripheral blood mononuclear cells from patients spontaneously secreted higher levels of TNF-alpha than did healthy controls, and receptor activator of NF-kappa B ligand (RANKL, a molecule that promotes osteoclast differentiation) expression was upregulated in the synovial lining layer, while osteoprotegerin (OPG, a soluble molecule that competitively binds RANKL) immunostaining was restricted to the endothelium. The authors of this study suggested that, in inflamed synovium and subchondral bone, osteoclast progenitors are exposed to unopposed RANKL and TNF-alpha. This leads to osteoclastogenesis at the erosion front and in subchondral bone. The resulting bidirectional assault on psoriatic bone thus leads to bony erosions. The mechanisms that lead to peripheral (ankylosis, periostitis, enthesophytes) and central (syndesmophytes) bone formation in PsA are not well-understood, although evidence does support the view that bone morphogenetic protein (BMP), Wnt, and prostaglandin E signaling pathways are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monocytes may also play a role in the pathogenesis of PsA. Resting monocytes from patients had significantly reduced density of a beta-2 integrin (CD11b) compared with controls, but activation of the monocytes generated upregulation of most adhesion molecules comparable to controls. The authors suggest that the impaired adhesion, as well as transendothelial migration of monocytes of patients with PsA, can be explained by the reduced expression of the",
"    <span class=\"nowrap\">",
"     CD11b/CD18",
"    </span>",
"    dimer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/71\">",
"     71",
"    </a>",
"    ]. In addition, increased production of",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    derived metalloproteinases has been demonstrated in the synovium of patients with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of a synovio-entheseal complex (SEC) has been proposed, in which, in health, the synovium provides nourishment and lubrication to the entheseal fibrocartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/73\">",
"     73",
"    </a>",
"    ]. When a mechanically stressed enthesis is injured, the associated inflammatory reaction would be manifested in the juxtaposed synovium. In a collagen-induced arthritis murine model, enthesitis and entheseal new bone formation were directed by CD3+CD4",
"    <sup>",
"     -",
"    </sup>",
"    CD8",
"    <sup>",
"     -",
"    </sup>",
"    T cells in response to IL-23 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/74\">",
"     74",
"    </a>",
"    ]. The demonstration of altered vascularity at enthesis insertion sites, particularly in the presence of microdamage and ensuing repair, suggests that local biomechanical factors and local trauma may also drive the entheseal inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL AND OTHER FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several environmental factors have been incriminated in the pathogenesis of psoriasis and PsA, including infections (both bacterial and viral) and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/59,76\">",
"     59,76",
"    </a>",
"    ]. For example, an association with streptococcal infection has been proposed, and this view is supported by improvement in skin lesions in psoriasis patients who underwent tonsillectomy and by the degree of clinical improvement correlated with a decrease in the frequency of peptide reactive (streptococcal M proteins, keratin) CLA",
"    <sup>",
"     +",
"    </sup>",
"    skin-homing T cells in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/77\">",
"     77",
"    </a>",
"    ]. The finding that 16S-based sequencing of psoriatic plaques showed increased bacterial diversity, including more Streptococcus, compared with skin biopsies from controls raised the possibility that microbiomal factors may drive inflammatory pathways in psoriatic skin and joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psoriasis may develop at sites of trauma (called the Koebner phenomenon). Furthermore, some patients with PsA provide a history of preceding trauma prior to the onset of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/47,79,80\">",
"     47,79,80",
"    </a>",
"    ]. A case-control study of patients with PsA and psoriasis identified rubella vaccination, injury, house moving, recurrent oral ulcers, and bone fractures to be associated with the development of inflammatory arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/80\">",
"     80",
"    </a>",
"    ]. Obesity, which is a risk factor for psoriasis, may also convey increased risk for PsA; body mass index at age 18 increased risk by a statistically significant but small degree [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/81\">",
"     81",
"    </a>",
"    ]. A case-control study identified lifting of heavy loads and infections requiring hospitalization as associated with the development of PsA; this study did not confirm the association of rubella vaccination or fractures with PsA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/82\">",
"     82",
"    </a>",
"    ]. An inverse association of smoking with PsA has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23608/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"       \"Patient information: Psoriatic arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21121079\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The precise causes of psoriatic arthritis (PsA) and psoriasis have not been identified. Genetic, immunologic, and environmental factors all contribute, and some mechanisms common to both are likely to play a role. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A role for genetic factors in the pathogenesis of PsA is supported by evidence of increased prevalence among certain families and in monozygotic twins; by the association of disease with certain histocompatibility antigens, which may affect prognosis; by linkages on several chromosomes identified with genome-wide scanning; and by individual candidate gene studies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A role for immunologic mechanisms is suggested by the inflammatory response in the psoriatic skin lesions and by the synovial lesions, which are, at times, indistinguishable from rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunologic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several environmental factors have been incriminated in the pathogenesis of psoriasis and PsA, including infections (both bacterial and viral) and trauma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Environmental and other factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/1\">",
"      Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/2\">",
"      Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/3\">",
"      Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 1998; 7:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/4\">",
"      Elder JT, Nair RP, Henseler T, et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol 2001; 137:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/5\">",
"      Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64 Suppl 2:ii37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/6\">",
"      Pedersen OB, Svendsen AJ, Ejstrup L, et al. On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins. Ann Rheum Dis 2008; 67:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/7\">",
"      Myers A, Kay LJ, Lynch SA, Walker DJ. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology (Oxford) 2005; 44:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/8\">",
"      Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009; 68:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/9\">",
"      Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 1999; 60:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/10\">",
"      Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 2012; 71:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/11\">",
"      Gladman DD, Farewell VT, Rahman P, et al. HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. Hum Immunol 2001; 62:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/12\">",
"      Korendowych E, Dixey J, Cox B, et al. The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. J Rheumatol 2003; 30:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/13\">",
"      Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998; 25:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/14\">",
"      Giardina E, H&uuml;ffmeier U, Ravindran J, et al. Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis Rheum 2011; 63:3801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/15\">",
"      Winchester R, Minevich G, Steshenko V, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012; 64:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/16\">",
"      Sakkas LI, Marchesoni A, Kerr LA, et al. Immunoglobulin heavy chain gene polymorphisms in Italian patients with psoriasis and psoriatic arthritis. Br J Rheumatol 1991; 30:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/17\">",
"      Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/18\">",
"      Martin MP, Nelson G, Lee JH, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/19\">",
"      Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995; 38:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/20\">",
"      Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997; 6:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/21\">",
"      Veal CD, Clough RL, Barber RC, et al. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 2001; 38:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/22\">",
"      Gladman DD, Farewell VT, Pellett F, et al. HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 2003; 64:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/23\">",
"      Allen MH, Veal C, Faassen A, et al. A non-HLA gene within the MHC in psoriasis. Lancet 1999; 353:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/24\">",
"      Oka A, Tamiya G, Tomizawa M, et al. Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. Hum Mol Genet 1999; 8:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/25\">",
"      Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 2000; 66:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/26\">",
"      Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/27\">",
"      Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012; 132:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/28\">",
"      Ellinghaus E, Stuart PE, Ellinghaus D, et al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol 2012; 132:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/29\">",
"      Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003; 72:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/30\">",
"      Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/31\">",
"      Rahman P, Bartlett S, Siannis F, et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003; 73:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/32\">",
"      Giardina E, Novelli G, Costanzo A, et al. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J Invest Dermatol 2004; 122:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/33\">",
"      Lascorz J, Burkhardt H, H&uuml;ffmeier U, et al. Lack of genetic association of the three more common polymorphisms of CARD15 with psoriatic arthritis and psoriasis in a German cohort. Ann Rheum Dis 2005; 64:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/34\">",
"      Ho P, Bruce IN, Silman A, et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005; 52:3596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/35\">",
"      Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012; 90:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/36\">",
"      Docampo E, Giardina E, Riveira-Mu&ntilde;oz E, et al. Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: a study in Spanish and Italian populations and meta-analysis. Arthritis Rheum 2011; 63:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/37\">",
"      Rahman P, Siannis F, Butt C, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006; 65:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/38\">",
"      Reich K, H&uuml;ffmeier U, K&ouml;nig IR, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007; 56:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/39\">",
"      Balding J, Kane D, Livingstone W, et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003; 48:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/40\">",
"      H&ouml;hler T, Grossmann S, Stradmann-Bellinghausen B, et al. Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 2002; 61:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/41\">",
"      Gonzalez S, Martinez-Borra J, Torre-Alonso JC, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999; 42:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/42\">",
"      Gonz&aacute;lez S, Brautbar C, Mart&iacute;nez-Borra J, et al. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 2001; 62:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/43\">",
"      Rahman P, Butt C, Siannis F, et al. Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations. Ann Rheum Dis 2005; 64:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/44\">",
"      Butt C, Peddle L, Greenwood C, et al. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. Arthritis Res Ther 2006; 8:R27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/45\">",
"      Rahman P, Sun S, Peddle L, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006; 54:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/46\">",
"      Rahman P, Inman RD, Maksymowych WP, et al. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol 2009; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/47\">",
"      Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008; 58:3705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/48\">",
"      H&uuml;ffmeier U, Lascorz J, B&ouml;hm B, et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009; 129:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/49\">",
"      Butt C, Sun S, Greenwood C, et al. Lack of association of SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 variants in psoriatic arthritis. Rheumatology (Oxford) 2005; 44:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/50\">",
"      H&uuml;ffmeier U, Traupe H, Burkhardt H, et al. Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts. J Invest Dermatol 2005; 124:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/51\">",
"      Bowes J, Ho P, Salah S, et al. IL-13 is a risk locus for psoriatic arthritis but not psoriasis vulgaris. Arthritis Rheum 2010; 62:S348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/52\">",
"      Eder L, Chandran V, Pellett F, et al. The association of IL-13 polymorphism with psoriatic arthritis among psoriasis patients. Arthritis Rheum 2010; 62:S830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/53\">",
"      Gladman DD. Toward unraveling the mystery of psoriatic arthritis. Arthritis Rheum 1993; 36:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/54\">",
"      McGonagle D, Ash Z, Dickie L, et al. The early phase of psoriatic arthritis. Ann Rheum Dis 2011; 70 Suppl 1:i71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/55\">",
"      Panayi GS. Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 1994; 8:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/56\">",
"      Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/57\">",
"      van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/58\">",
"      Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007; 46:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/59\">",
"      Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/60\">",
"      Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7:R569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/61\">",
"      Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/62\">",
"      Costello P, Bresnihan B, O'Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999; 26:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/63\">",
"      Tassiulas I, Duncan SR, Centola M, et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/64\">",
"      Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012; 359:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/65\">",
"      Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/66\">",
"      McQueen FM, Skinner MA, Krissansen GW, et al. Natural killer cell function and expression of beta 7 integrin in psoriatic arthritis. J Rheumatol 1994; 21:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/67\">",
"      Companjen A, van der Wel L, van der Fits L, et al. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur Cytokine Netw 2004; 15:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/68\">",
"      Rooney T, Murphy E, Benito M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004; 63:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/69\">",
"      Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/70\">",
"      Beyer C, Schett G. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage. Best Pract Res Clin Rheumatol 2010; 24:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/71\">",
"      Neum&uuml;ller J, Dunky A, Burtscher H, et al. Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin Immunol 2001; 98:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/72\">",
"      Hitchon CA, Danning CL, Illei GG, et al. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J Rheumatol 2002; 29:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/73\">",
"      McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a \"synovio-entheseal complex\" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/74\">",
"      Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-&gamma;t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/75\">",
"      Benjamin M, Toumi H, Suzuki D, et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007; 56:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/76\">",
"      Prinz JC. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/77\">",
"      Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 2012; 188:5160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/78\">",
"      Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol 2011; 9:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/79\">",
"      Scarpa R, Del Puente A, di Girolamo C, et al. Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann Rheum Dis 1992; 51:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/80\">",
"      Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 2008; 67:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/81\">",
"      Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010; 146:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/82\">",
"      Eder L, Loo T, Chandran V, et al. Environmental risk factors for psoriatic arthritis among patients with psoriasis: A case-control study. Arthritis Rheum 2010; 62:S809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23608/abstract/83\">",
"      Eder L, Shanmugarajah S, Thavaneswaran A, et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012; 71:219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7791 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23608=[""].join("\n");
var outline_f23_3_23608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21121079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HLA antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genome-wide scans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Candidate genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMUNOLOGIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENVIRONMENTAL AND OTHER FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21121079\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=related_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_3_23609="Overview of smoking cessation management in adults";
var content_f23_3_23609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of smoking cessation management in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Stephen I Rennard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Nancy A Rigotti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23609/contributors\">",
"     David M Daughton, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23609/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/3/23609/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/3/23609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13309623\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is the leading preventable cause of mortality. Smokers who stop smoking reduce their risk of developing and dying from tobacco-related diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Approximately 70 percent of smokers say in surveys that they want to quit, and over 40 percent of smokers report that they tried to quit in the past year and intentionally did not smoke for at least one day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the long-term success rate of any one unaided quit attempt is low, with only 3 to 7 percent of smokers who make an attempt still abstinent one year later. With optimal treatment, one-year abstinence rates after a single quit attempt can exceed 30 percent, yet only 25 percent of smokers who try to quit seek help and even fewer use the most effective treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses of clinical trials have found that behavioral counseling and pharmacotherapy (with nicotine replacement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    ) each has strong evidence of efficacy for smoking cessation, and that the combination of the two methods produces the best results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This topic provides an overview of smoking cessation management in adults, including the choice of therapy and how to implement treatment. Management of smoking cessation in adolescents and pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41497?source=see_link\">",
"     \"Management of smoking cessation in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link&amp;anchor=H19#H19\">",
"     \"Smoking and pregnancy\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patterns of tobacco use and behavioral and pharmacologic treatments for smoking cessation are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23644659\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF USE AND EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Health Services guidelines recommend that tobacco use status of every patient treated in a healthcare setting be assessed and documented at every visit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/7\">",
"     7",
"    </a>",
"    ]. This practice has been shown to increase the likelihood of smoking-related discussions between patients and physicians and to increase smoking cessation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician should first assess the patient's tobacco use, the desire to stop smoking, and the history of previous quit attempts, including methods used and their effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/11\">",
"     11",
"    </a>",
"    ]. A smoker&rsquo;s dependence on nicotine can be estimated from the duration of smoking history, the number of cigarettes smoked daily, and how soon after waking up the smoker has his or her first morning cigarette. More dependent smokers have smoked for many years, smoke more cigarettes daily, and smoke within the first 30 minutes of awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The smoker's degree of nicotine dependence predicts the difficulty that he or she will have in quitting and the intensity of treatment likely to be required.",
"   </p>",
"   <p>",
"    While most of the discussion in this topic refers to cigarette smoking, cigar smoking and smokeless tobacco use are also associated with significant health risks and should be assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link&amp;anchor=H279603278#H279603278\">",
"     \"Patterns of tobacco use\", section on 'Nicotine sources'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general health assessment should also include exposure to secondhand smoke in nonsmoking patients. Exposure to secondhand smoke is associated with an increased risk of coronary heart disease and lung cancer in nonsmokers. Nonsmokers should be queried about regular exposure to tobacco use at home and at work. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23644472\">",
"    <span class=\"h1\">",
"     ADDRESSING BARRIERS TO QUIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors account for the difficulty that smokers encounter when they try to quit. The addictiveness of nicotine is the primary barrier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5263325\">",
"    <span class=\"h2\">",
"     Nicotine withdrawal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotine is a potent psychoactive drug that causes physical dependence and tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/13\">",
"     13",
"    </a>",
"    ]. In the absence of nicotine, a smoker develops cravings for cigarettes and symptoms of the nicotine withdrawal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/14\">",
"     14",
"    </a>",
"    ]. These symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysphoric or depressed mood",
"     </li>",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Irritability, frustration, or anger",
"     </li>",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      Difficulty concentrating",
"     </li>",
"     <li>",
"      Restlessness",
"     </li>",
"     <li>",
"      Increased appetite or weight gain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors should be addressed, so that smokers will know what to expect and how to respond if these symptoms occur. Specific problem solving skills are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5263340\">",
"    <span class=\"h2\">",
"     Other barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, smokers become conditioned to associate the pleasurable effects of tobacco use with environmental triggers such as their morning coffee, an alcoholic drink, or the end of a meal. These triggers contribute to the difficulty smokers have in remaining abstinent from nicotine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/3\">",
"     3",
"    </a>",
"    ]. Smokers need to anticipate triggers and find ways to overcome them (eg, avoid trigger exposure, engage in other activities such as exercise, elicit a support system such as a friend or telephone helpline).",
"   </p>",
"   <p>",
"    Many smokers who have failed to quit smoking state that they have \"tried everything\" when in fact they may have not engaged in any formal smoking cessation counseling program and may have not used medications adequately. All smokers should be told that the clinician is willing to help to work through any obstacles and that effective treatments are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313634\">",
"    <span class=\"h1\">",
"     CHOICE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, clinicians should offer smokers both behavioral and pharmacologic therapy, as these treatments in combination are found to most effectively promote abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H525961471\">",
"     'For the general population'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525960917\">",
"    <span class=\"h2\">",
"     Types of treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525960924\">",
"    <span class=\"h3\">",
"     Behavioral counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral counseling can be provided in a variety of formats, including direct patient-clinician encounters, via telephone, computer programs, text-messaging, or group-based therapy. The most intensive behavioral intervention acceptable to the patient should be offered. For many patients, this will be only brief clinician counseling in the office. A simple five-step algorithm called the 5 A's (Ask, Advise, Assess, Assist, Arrange) that operationalizes the elements of brief counseling for office practice are effective for increasing abstinence rates (",
"    <a class=\"graphic graphic_table graphicRef74402 \" href=\"UTD.htm?40/33/41500\">",
"     table 1",
"    </a>",
"    ). The approach to behavioral counseling and benefits of individual counseling strategies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525960931\">",
"    <span class=\"h3\">",
"     Pharmacologic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line drug therapy for smokers includes nicotine replacement therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    . Each of these medications has proven efficacy for smoking cessation. Each medication has a different side effect profile and may be preferentially used in different patient populations (eg, bupropion for patients with schizophrenia). Pharmacologic therapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525960938\">",
"    <span class=\"h3\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other types of interventions have been used for smoking cessation, without proven efficacy. These include acupuncture, aversive therapy, and hypnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acupuncture - Acupuncture is included in some commercially available smoking cessation programs. However, a meta-analysis of randomized trials found no differences in long-term abstinence rates for acupuncture, compared to sham acupuncture or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/15\">",
"       15",
"      </a>",
"      ], although a separate meta-analysis suggested potential benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/16\">",
"       16",
"      </a>",
"      ]. Acupuncture was found to be less effective than nicotine replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"       \"Acupuncture\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aversive therapy - Aversive therapy for smoking cessation involves increasing the amount and rate of cigarette smoking over a short period of time with the goal of inducing a sense of displeasure with smoking. A meta-analysis of 25 randomized trials found insufficient evidence to support a clear dose-response relationship between aversive therapy and smoking cessation, but suggested further studies are needed to clarify its efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Financial incentives for quitting smoking may improve rates of smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/18\">",
"       18",
"      </a>",
"      ]. A randomized trial among 878 smokers employed at a company in the US found that a substantial financial incentive (as much as $750) increased smoking cessation rates at 9 or 12 months (15 versus 5 percent) and at 15 or 18 months (9 versus 4 percent), compared to an information-only control [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/19\">",
"       19",
"      </a>",
"      ]. Despite some evidence of efficacy, further studies are needed to determine how to optimize financial incentives at lowest cost, if benefits can be maintained over the long-term, and how to prevent gaming of payment systems [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypnosis - A systematic review of 11 randomized trials found insufficient data to support the use of hypnotherapy for smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/20\">",
"       20",
"      </a>",
"      ], although a separate meta-analysis suggested potential benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525961471\">",
"    <span class=\"h2\">",
"     For the general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients who wish to quit smoking be managed with a combination of behavioral and pharmacologic treatments. Meta-analyses of clinical trials have found that the combination of behavioral counseling and pharmacotherapy (with nicotine replacement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    ) is more effective than pharmacotherapy alone (OR 1.4, 95% CI 1.2-1.6) or counseling alone (OR 1.7, CI 1.3-2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/4\">",
"     4",
"    </a>",
"    ]. The individual behavioral and pharmacologic therapies (including efficacy, dosing, duration, and adverse effects) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies demonstrate increasing quit rates with increasing behavioral support [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the most intensive intervention available, such as a specialty clinic or smoking cessation program, should be offered to the patient. When a specialty center referral is unavailable or declined by the patient, the \"maximum acceptable\" behavioral therapy will often be a brief, office-based intervention that should be supplemented by referring the smoker for free telephone counseling. Free telephone counseling in the United States can be accessed through a single toll-free nationwide telephone number (1-800-QUIT-NOW). The services provided vary by quitline, but most quitlines offer to call a smoker proactively several times while they are in the quitting process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Public Health Service (USPHS) smoking cessation guidelines do not recommend any one of the first-line pharmacologic agents over another [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/4\">",
"     4",
"    </a>",
"    ]. Instead, they recommend that patient preference, previous experience with the drugs, and medical conditions guide the choice among the first-line drugs (ie, nicotine replacement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/4\">",
"     4",
"    </a>",
"    ]. We regard varenicline or the combination of patch plus short acting nicotine replacement therapy as roughly-equivalent first-line pharmacotherapy. Combination nicotine replacement therapy is a good choice for individuals where the safety of varenicline is a concern (eg, history of suicidal ideation). Bupropion or single-type nicotine replacement therapy are reasonable alternatives based on cost, patient preferences, comorbid diseases (particularly psychiatric diseases), and side effect profiles. Bupropion may be a good choice for smokers who are especially concerned about post-cessation weight gain, which bupropion blunts temporarily. Choosing specific drug therapies for smoking cessation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H525960336#H525960336\">",
"     \"Pharmacotherapy for smoking cessation in adults\", section on 'Choosing medication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313649\">",
"    <span class=\"h2\">",
"     For special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;All smokers should receive behavioral counseling; however, the decision to use pharmacotherapy and the choice of individual medications vary based on a given patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13315396\">",
"    <span class=\"h3\">",
"     Psychiatric illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking is highly prevalent among patients with mental illness, but these patients are less likely to be treated compared to patients without mental illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/21\">",
"     21",
"    </a>",
"    ]. Behavioral and pharmacologic therapies can increase abstinence rates in smokers with psychiatric illness.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    , in particular, may be helpful for smoking cessation in patients with depression and schizophrenia, but can exacerbate illness in patients with bipolar disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression - For patients with mild untreated depression,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      is theoretically an attractive first line agent since it has the ability to treat both depression and smoking. However, there is no evidence from clinical trials demonstrating the superiority of bupropion over other agents in this group of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/22\">",
"       22",
"      </a>",
"      ]. In patients with more severe depression who are receiving multiple antidepressant agents, coordination of care with the patient's psychiatrist is essential before making pharmacotherapeutic recommendations, especially for bupropion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Schizophrenia &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      is considered first-line therapy for smoking cessation in patients with schizophrenia. In a meta-analysis including five randomized trials of patients with schizophrenia, smoking cessation rates at six month follow-up were higher with bupropion compared to placebo (RR 2.78, 95% 1.02-7.58) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/23\">",
"       23",
"      </a>",
"      ]. There was no evidence of benefit of nicotine replacement treatment or psychosocial interventions in smokers with schizophrenia. Randomized trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      are underway.",
"     </li>",
"     <li>",
"      Bipolar disorder - Antidepressant therapy may trigger mania in patients with bipolar disorder. For this reason, we avoid",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      in smokers with bipolar disorder. Nicotine replacement may be a good first-line choice for these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link&amp;anchor=H170721354#H170721354\">",
"       \"Bipolar disorder in adults: Maintenance treatment\", section on 'Potentially problematic drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313664\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued smoking is a major risk factor for adverse cardiovascular events in patients with cardiovascular disease (CVD). Smoking cessation is particularly beneficial in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of smoking cessation in patients with stable CVD is similar to the management of patients without CVD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavioral approaches to smoking cessation are effective for long-term abstinence [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although there have been concerns about the use of nicotine replacement therapy in this population, studies have found nicotine replacement therapy to be safe and effective in smokers with stable CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      is also safe and effective in smokers with stable CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cardiovascular safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      in smokers with CVD is being tested. Over the long term, even in a higher risk population of patients with stable CVD, the benefits of smoking cessation likely outweigh any potential adverse effects of varenicline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data regarding the risks of adverse events of these medications in patients with CVD are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link\">",
"     \"Pharmacotherapy for smoking cessation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313671\">",
"    <span class=\"h3\">",
"     Hospitalized smokers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of smoke-free policies in many hospitals, hospitalization provides smokers with an opportunity to experience a period of nonsmoking in a setting that is free of the usual cues to smoke. The illness precipitating the admission may also reinforce the smoker's perceived vulnerability to the harms of tobacco use and motivate a quit attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This need not be directly related to smoking-induced disease; for example, patients who have undergone surgery are more likely to quit smoking than smokers who have not had surgery. Quit rates are also higher after major surgery than after outpatient procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Counseling offered to smokers who are hospitalized is effective. A 2012 meta-analysis of randomized trials found that intensive counseling (at least one contact during the hospital stay with continued support for at least one month after discharge; 25 trials) increased the likelihood of smoking cessation (relative risk [RR] 1.37, 95% CI 1.27-1.48) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/30\">",
"     30",
"    </a>",
"    ]. Less-intensive interventions did not appear to affect rates of smoking cessation.",
"   </p>",
"   <p>",
"    This same meta-analysis found that pharmacotherapy, at least with nicotine replacement therapy (six trials), appeared to improve smoking cessation compared with intensive counseling alone (RR 1.54, CI 1.34-1.79);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    (two trials) showed a trend toward improved rates (RR 1.28, CI 0.95-1.74), while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    (three trials) did not show additive benefit (RR 1.04, CI 0.75-1.45) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/30\">",
"     30",
"    </a>",
"    ]. There is additional rationale for using nicotine replacement therapy in the hospital setting in order to reduce nicotine withdrawal symptoms in smokers who are uncomfortable when a hospital admission forces them to abstain from smoking temporarily.",
"   </p>",
"   <p>",
"    It is not clear what agent should be used as first-line therapy in smokers with unstable CVD, including acute coronary syndrome (ACS). In a randomized trial of 151 smokers presenting with ACS, there was no difference in smoking cessation rates of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/31\">",
"     31",
"    </a>",
"    ]. All patients in this trial received intensive nurse counseling. Nicotine replacement therapy is commonly used among smokers with unstable CVD and appears to have some efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313678\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions tailored specifically to pregnant women are associated with high cessation rates. Pharmacotherapy in pregnant women is recommended only for those who are heavy smokers and are unable to quit on their own. Management of smoking cessation in pregnant women is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link&amp;anchor=H19#H19\">",
"     \"Smoking and pregnancy\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313685\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents who smoke frequently cite concerns about future and current health, physical appearance, cost of cigarettes, and athletic performance. Strategies to support smoking cessation, including behavioral intervention and nicotine replacement, are similar to strategies used in adults but should be adapted to the special concerns of this age group. Management of smoking cessation in adolescents is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41497?source=see_link\">",
"     \"Management of smoking cessation in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53797910\">",
"    <span class=\"h3\">",
"     Light smokers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light smokers are defined as those who smoke less than 10 cigarettes per day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/4\">",
"     4",
"    </a>",
"    ]. Light smokers comprise approximately a quarter of the adult smoking population. Although the adverse effects associated with smoking are dose-dependent, even light smoking is associated with increased mortality and several smoking-related diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/34\">",
"     34",
"    </a>",
"    ]. Behavioral counseling is the first-line treatment for light smokers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18968?source=see_link\">",
"     \"Benefits and risks of smoking cessation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacotherapy can also be used in light smokers who do not respond to behavioral therapy. In general, randomized trials have evaluated daily, heavy smokers; therefore, there are few data to guide dosing for light smokers or smokers who do not smoke every day (intermittent smokers). The doses of nicotine replacement therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    should be reduced for use in this population. Nicotine replacement therapy is an appropriate option given the dosage and frequency of use can be adjusted based on nicotine withdrawal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143742507\">",
"    <span class=\"h1\">",
"     MANAGING SMOKERS READY TO QUIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every smoker should be asked if he or she is interested in quitting smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/4\">",
"     4",
"    </a>",
"    ]. If motivated to quit, smokers should have access to appropriate resources to assist in smoking cessation. Many smokers mistakenly consider stopping smoking to be a task requiring only a brief application of willpower. In fact, most former smokers had to try to quit several times before they finally achieved success. Tobacco dependence is a problem better regarded as a chronic disease requiring long-term management to achieve permanent abstinence. In this way, its management has similarities to the management of other conditions such as diabetes and hypertension, which require long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians have the opportunity to help smokers by ensuring that smokers use effective treatments when they quit. Several practical steps in assisting a patient to stop smoking are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef52690 \" href=\"UTD.htm?39/23/40316\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinician should assess the smoker's previous experiences with attempts to quit. Assessing the methods that have been tried and the smoker's degree of success with each is important in order to guide recommendations for the next attempt.",
"   </p>",
"   <p>",
"    All smokers should be offered assistance in quitting that includes referral to the most intensive smoking cessation counseling program that is acceptable to the smoker and a discussion of smoking cessation medications. The clinician should also express confidence in the smoker's ability to quit and offer support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H525960336#H525960336\">",
"     \"Pharmacotherapy for smoking cessation in adults\", section on 'Choosing medication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143742514\">",
"    <span class=\"h2\">",
"     Setting a quit date",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of smoking cessation generally begins by setting a \"quit day\" within the next two weeks. Patients should be directed to stop smoking completely on their quit day and should be prepared to handle nicotine withdrawal symptoms.",
"   </p>",
"   <p>",
"    Some patients begin to reduce smoking in the days and weeks prior to the quit date. In a systematic review of ten randomized trials, there was no difference in abstinence rates between those who reduced smoking before the quit date and those who quit abruptly (RR 0.94, 95% CI 0.79-1.13), regardless of using behavioral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacologic treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, patients can be given the choice to reduce smoking prior to a quit date or to stop smoking abruptly on the quit date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313727\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up visit should be scheduled within three to seven days of the patient's quit day to provide reinforcement and monitor response to smoking cessation therapy. If a smoker is unable to return for an appointment, then contact by telephone should be scheduled, either from the clinician's office or from a telephone quitline. Patients should then be followed monthly for at least three months. &nbsp;",
"   </p>",
"   <p>",
"    Regardless of whether the patient has successfully quit smoking, clinicians should address any problems encountered as a result of smoking cessation, such as weight gain, depression, or a change in relationships with friends or relatives who smoke. These issues may lead to treatment failure or relapse anytime after a successful quit attempt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313734\">",
"    <span class=\"h3\">",
"     Difficulty quitting and relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a patient who fails to quit smoking after the quit day, the clinician should carefully review the patient's experience during the attempt to quit, try to work through any problems that are identified, and explore solutions for the next quit attempt (",
"    <a class=\"graphic graphic_table graphicRef54759 \" href=\"UTD.htm?43/36/44620\">",
"     table 3",
"    </a>",
"    ). These patients may be highly dependent upon nicotine, may have low self-confidence or little social support for quitting, may have comorbid psychiatric illness, or may not have been using medications optimally, all of which should be addressed with the patient before setting another quit date. The clinician should also determine the patient's own insight into the possible reasons why the attempt failed, most importantly how the patient is able to cope with withdrawal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following relapse, smokers should be encouraged to stop smoking. Nearly two-thirds of smokers who relapse report wanting to quit again within 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients should be reminded that most smokers require multiple attempts at smoking cessation before permanently quitting. If a previous medication was helpful temporarily, we typically recommend the same therapy that worked for the patient previously. This strategy may be enhanced with more intensive behavioral support",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combining with another medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H525960336#H525960336\">",
"     \"Pharmacotherapy for smoking cessation in adults\", section on 'Choosing medication'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have failed to quit often have had inadequate behavioral support as part of their treatment. For these patients, we attempt to intensify the behavioral counseling, suggesting formal in-person smoking cessation counseling. Referral to a subspecialty clinic or smoking cessation program for the smoker who is heavily dependent upon nicotine or has had multiple unsuccessful attempts is advised. Involving different types of providers (eg, physicians, nurses, psychologists, dentists) through a multidisciplinary program can improve smoking cessation rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In making changes to medication, it is important to distinguish between failure due to an inadequate trial of the medication (eg, chewing nicotine gum too rapidly), failure of the medication to reduce nicotine withdrawal, or intolerance of medication side effects. Smokers who had severe withdrawal symptoms should have the medication dose increased or use a combination of medications. Nicotine replacement therapy can be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    . There may be value in combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    with either nicotine replacement or bupropion, but the safety and efficacy of these combinations have not been well-established. Patients who did not tolerate the side effects of one pharmacologic therapy can try a lower dose or an alternate medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H64323787#H64323787\">",
"     \"Pharmacotherapy for smoking cessation in adults\", section on 'Adjusting therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520009954\">",
"    <span class=\"h3\">",
"     Relapse prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse prevention should be part of every encounter with a patient who has recently quit. Long-term follow-up is recommended because successful quitters can remain at high risk of relapse for several years after smoking cessation. Thirty-five to forty percent of patients relapse between years one and five after quitting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence from randomized trials indicates that continued pharmacotherapy can prevent relapse, up to 18 months after quitting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/42\">",
"     42",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     Varenicline",
"    </a>",
"    appears to have the best efficacy, but nicotine replacement and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    also appear to be efficacious. There is little evidence of harm from a longer duration of treatment with these medications, although the optimal duration has not been established. The primary issue is that most insurance companies do not cover smoking cessation medications after three months of pharmacotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H13314630#H13314630\">",
"     \"Pharmacotherapy for smoking cessation in adults\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is relatively little evidence that specific behavioral interventions prevent relapse after smoking cessation is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/42\">",
"     42",
"    </a>",
"    ]. However, it is reasonable to use simple interventions that promote abstinence (",
"    <a class=\"graphic graphic_table graphicRef54759 \" href=\"UTD.htm?43/36/44620\">",
"     table 3",
"    </a>",
"    ). The clinician should encourage and congratulate the patient on quitting. The benefits of smoking cessation can be highlighted by simply asking how their lives have changed since they stopped smoking. An equally important step is to address any problems encountered as a result of abstinence (eg, weight gain, depression, alcohol use).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143742026\">",
"    <span class=\"h1\">",
"     ENCOURAGING SMOKERS NOT READY TO QUIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For smokers who are not ready to quit, the clinician's role is to assess the patient's perspective (of the risks and benefits of continuing to smoke) in order to help the smoker to begin to think about quitting. Most smokers have a general desire to stop smoking, but may not be ready to take specific action to quit, for a variety of reasons. Asking a smoker what he or she likes and does not like about smoking is a way to start. A personalized message concerning a smoking-related health problem may motivate some patients into action.",
"   </p>",
"   <p>",
"    Clinicians can use motivational interviewing techniques to explore a smoker&rsquo;s feelings, beliefs, ideas, and values regarding tobacco use. The model of \"5 Rs\" (Relevance, Risks, Rewards, Roadblocks, Repetition) is helpful to motivate smokers who are not ready to quit (",
"    <a class=\"graphic graphic_table graphicRef70628 \" href=\"UTD.htm?17/58/18349\">",
"     table 4",
"    </a>",
"    ). Motivating a patient to quit smoking is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smokers who are not interested in quitting now can also be advised about the health risks of secondhand smoke exposure to their household members and urged to commit to keeping their home and car smoke-free, especially if children are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125254283\">",
"    <span class=\"h2\">",
"     Questionable utility of smoking reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing the number of cigarettes smoked daily has been advocated as a possible alternative to complete cessation in patients who are unable to quit smoking. However, few data are available that support a strategy for a reduction in smoking, compared to complete cessation. Consistent benefits in CVD risk have not been seen with reduction in smoking short of quitting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/43\">",
"     43",
"    </a>",
"    ]. This is because even low levels of tobacco smoke exposure increase cardiovascular risk. At least two prospective cohort studies found that smokers who reduced smoking by at least 50 percent had no change in all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], whereas those who quit smoking completely had decreased risk of all-cause mortality.",
"   </p>",
"   <p>",
"    However, a cohort study that followed 4633 Israeli men from 1965 through 2005 found reduced risk for mortality associated with smoking reduction (hazard ratio 0.85, 95% CI 0.77-0.95); the benefit with smoking reduction was mainly seen in heavy smokers and was mainly due to a reduction in CV mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/46\">",
"     46",
"    </a>",
"    ]. A separate cohort study also found that a reduction in smoking may decrease the risk of lung cancer (",
"    <a class=\"graphic graphic_table graphicRef50077 \" href=\"UTD.htm?13/40/13963\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/3/23609/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H7#H7\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Smoking reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One reason that a reduction in smoking may not consistently improve health outcomes is that smokers may compensate for smoking reduction with increased puffs, volume, or duration in order to maintain nicotine intake and forestall nicotine withdrawal symptoms. Smoking reduction remains controversial as a strategy for reducing the health risks of smokers. Complete smoking cessation is preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       \"Patient information: Quitting smoking (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       \"Patient information: Cough in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=see_link\">",
"       \"Patient information: Secondhand smoke: Risks to children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13313748\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessing tobacco use status during healthcare visits increases the likelihood of smoking-related discussions between patients and clinicians, as well as increases smoking cessation rates. The clinician should assess the patient's cigarette use, the desire to stop smoking, and the history of previous attempts to quit, including methods used and their effectiveness. (See",
"      <a class=\"local\" href=\"#H23644659\">",
"       'Assessment of use and exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For smokers who are willing to quit, we recommend that smokers be managed with a combination of behavioral support and pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Combination therapy is superior to either behavioral intervention or pharmacologic therapy alone. We suggest that the maximal behavioral intervention acceptable to the patient be used. In most settings, behavioral intervention generally consists of brief clinician counseling in the office, but smokers should also be referred to a free telephone quitline for continued counseling support. In the United States, this can be accessed through a national toll-free number (1-800-QUIT-NOW). (See",
"      <a class=\"local\" href=\"#H13313634\">",
"       'Choice of treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"       \"Smoking cessation counseling strategies in primary care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      or combined nicotine replacement (a patch plus a short-acting form such as the gum or lozenge) as first line pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination nicotine replacement therapy is a good choice in individuals for whom the safety of varenicline is a concern (eg, history of suicidal ideation).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      or single-type nicotine replacement therapy is a reasonable alternative based on cost, patient preferences, comorbid diseases, and side effect profiles. Bupropion may be a good choice for smokers who are especially concerned about post-cessation weight gain, which bupropion blunts temporarily. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H525960336#H525960336\">",
"       \"Pharmacotherapy for smoking cessation in adults\", section on 'Choosing medication'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are unable to quit with individual agents or combination nicotine replacement therapy, we suggest using combination pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable combination is one or two forms of nicotine replacement therapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      . We also attempt to intensify behavioral counseling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H64323787#H64323787\">",
"       \"Pharmacotherapy for smoking cessation in adults\", section on 'Adjusting therapy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13313734\">",
"       'Difficulty quitting and relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who successfully quit but experience relapse be treated with the pharmacologic agent that previously worked for the patient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This strategy may be enhanced by combining therapy with another medication or with more intensive behavioral support. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=see_link&amp;anchor=H64323787#H64323787\">",
"       \"Pharmacotherapy for smoking cessation in adults\", section on 'Adjusting therapy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13313734\">",
"       'Difficulty quitting and relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For smokers who are not ready to quit, the clinician's role is to assess the patient's perspective of the risks and benefits of continuing to smoke, in order to help the smoker to begin to think about quitting. Clinicians should also use motivational interviewing techniques to explore a smoker&rsquo;s feelings, beliefs, ideas, and values regarding tobacco use. The United States Preventive Health Services (USPHS) guideline has proposed the model of \"5 Rs\" (Relevance, Risks, Rewards, Roadblocks, Repetition) in promoting motivation in patients who are unwilling to quit (",
"      <a class=\"graphic graphic_table graphicRef70628 \" href=\"UTD.htm?17/58/18349\">",
"       table 4",
"      </a>",
"      ). Encouraging a patient&rsquo;s motivation to quit smoking is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"       \"Smoking cessation counseling strategies in primary care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/1\">",
"      Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; :CD003041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/2\">",
"      Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/3\">",
"      Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002; 346:506.",
"     </a>",
"    </li>",
"    <li>",
"     Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services 2008. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/5\">",
"      Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012; 10:CD008286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/6\">",
"      Suls JM, Luger TM, Curry SJ, et al. Efficacy of smoking-cessation interventions for young adults: a meta-analysis. Am J Prev Med 2012; 42:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/7\">",
"      A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/8\">",
"      Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; :CD000165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/9\">",
"      Robinson MD, Laurent SL, Little JM Jr. Including smoking status as a new vital sign: it works! J Fam Pract 1995; 40:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/10\">",
"      Okuyemi KS, Ahluwalia JS, Wadland WC. The evaluation and treatment of tobacco use disorder. J Fam Pract 2001; 50:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/11\">",
"      West R. Assessment of dependence and motivation to stop smoking. BMJ 2004; 328:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/12\">",
"      Heatherton TF, Kozlowski LT, Frecker RC, Fagerstr&ouml;m KO. The Fagerstr&ouml;m Test for Nicotine Dependence: a revision of the Fagerstr&ouml;m Tolerance Questionnaire. Br J Addict 1991; 86:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/13\">",
"      Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 1985; 234:1.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/15\">",
"      White AR, Rampes H, Liu JP, et al. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2011; :CD000009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/16\">",
"      Tahiri M, Mottillo S, Joseph L, et al. Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med 2012; 125:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/17\">",
"      Hajek P, Stead LF. Aversive smoking for smoking cessation. Cochrane Database Syst Rev 2004; :CD000546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/18\">",
"      Aveyard P, Bauld L. Incentives for promoting smoking cessation: What we still do not know. Cochrane Database Syst Rev 2011; :ED000027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/19\">",
"      Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2009; 360:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/20\">",
"      Barnes J, Dong CY, McRobbie H, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 2010; :CD001008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/21\">",
"      Prochaska JJ. Smoking and mental illness--breaking the link. N Engl J Med 2011; 365:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/22\">",
"      Gierisch JM, Bastian LA, Calhoun PS, et al. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med 2012; 27:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/23\">",
"      Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2010; :CD007253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/24\">",
"      Barth J, Critchley J, Bengel J. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev 2008; :CD006886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/25\">",
"      Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/26\">",
"      Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/27\">",
"      Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 2008; 168:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/28\">",
"      Keenan PS. Smoking and weight change after new health diagnoses in older adults. Arch Intern Med 2009; 169:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/29\">",
"      Shi Y, Warner DO. Surgery as a teachable moment for smoking cessation. Anesthesiology 2010; 112:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/30\">",
"      Rigotti NA, Clair C, Munaf&ograve; MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2012; 5:CD001837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/31\">",
"      Planer D, Lev I, Elitzur Y, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 2011; 171:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/32\">",
"      Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005; 80:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/33\">",
"      Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007; 131:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/34\">",
"      Prescott E, Scharling H, Osler M, Schnohr P. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health 2002; 56:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/35\">",
"      Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med 2008; 148:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/36\">",
"      Lindson N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2010; :CD008033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/37\">",
"      Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care 2006; 12:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/38\">",
"      Hajek P, Stead LF, West R, et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; :CD003999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/39\">",
"      Stapleton JA, Sutherland G, Russell MA. How much does relapse after one year erode effectiveness of smoking cessation treatments? Long-term follow up of randomised trial of nicotine nasal spray. BMJ 1998; 316:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/40\">",
"      Mikkelsen KL, T&oslash;nnesen P, N&oslash;rregaard J. Three-year outcome of two- and three-year sustained abstainers from a smoking cessation study with nicotine patches. J Smok Rel Dis 1994; 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/41\">",
"      Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/42\">",
"      Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105:1362.",
"     </a>",
"    </li>",
"    <li>",
"     Office of the Surgeon General. Chapter Six: Cardiovascular diseases. In: A Report of the Surgeon General: How Tobacco Smoke Causes Disease. US Department of Health and Human Services 2011. Available at: file://www.surgeongeneral.gov/library/tobaccosmoke/report/chapter6.pdf (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/44\">",
"      Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control 2006; 15:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/45\">",
"      Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 2002; 156:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/46\">",
"      Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: a prospective cohort study. Am J Epidemiol 2012; 175:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/3/23609/abstract/47\">",
"      Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294:1505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16634 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23609=[""].join("\n");
var outline_f23_3_23609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13313748\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13309623\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23644659\">",
"      ASSESSMENT OF USE AND EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23644472\">",
"      ADDRESSING BARRIERS TO QUIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5263325\">",
"      Nicotine withdrawal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5263340\">",
"      Other barriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13313634\">",
"      CHOICE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525960917\">",
"      Types of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525960924\">",
"      - Behavioral counseling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525960931\">",
"      - Pharmacologic treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H525960938\">",
"      - Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525961471\">",
"      For the general population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13313649\">",
"      For special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13315396\">",
"      - Psychiatric illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13313664\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13313671\">",
"      - Hospitalized smokers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13313678\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13313685\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53797910\">",
"      - Light smokers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H143742507\">",
"      MANAGING SMOKERS READY TO QUIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143742514\">",
"      Setting a quit date",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13313727\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13313734\">",
"      - Difficulty quitting and relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H520009954\">",
"      - Relapse prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H143742026\">",
"      ENCOURAGING SMOKERS NOT READY TO QUIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H125254283\">",
"      Questionable utility of smoking reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13313748\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16634|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/33/41500\" title=\"table 1\">",
"      Five As for smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/23/40316\" title=\"table 2\">",
"      Assisting patients with smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/36/44620\" title=\"table 3\">",
"      Preventing and managing smoking relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/58/18349\" title=\"table 4\">",
"      Five Rs smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/40/13963\" title=\"table 5\">",
"      Risk after reducing smoking",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18968?source=related_link\">",
"      Benefits and risks of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41497?source=related_link\">",
"      Management of smoking cessation in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=related_link\">",
"      Patient information: Secondhand smoke: Risks to children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/13/17626?source=related_link\">",
"      Pharmacotherapy for smoking cessation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_3_23610="HHV-6 detected in the brain";
var content_f23_3_23610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Active human herpesvirus 6 (HHV-6) infection in the brain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 662px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Viral mRNA detected in fresh/frozen brain tissue by nested reverse transcription-polymerase chain reaction (RT-PCR) for the HHV-6 early gene p41 (100 bp) and beta-actin (275 bp). Lane 1, left hippocampus; lane 2, right hippocampus; lane 3, left insular cortex; lane 4, right cingular gyrus; lane 5, control hippocampus; lane 6, HHV-6B (strain Z29)-infected T cell-positive control; lane 7, uninfected cells; lane 8, no template control.",
"    <br>",
"     (B) HHV-6 antigen expression detected by immunohistochemistry for the late HHV-6 protein gp116/54/64. a, Patient 1, right cingular gyrus; b, right parietal lobe; c and f, negative control hippocampus; d, patient 2 hippocampus; e, patient 3 right parietal lobe. gp116 was localized to the hippocampus in patients 1 (g), 2 (h), and 3 (i). Magnification, 100x (a-c) or 40x (d-i). Hematoxylin-eosin-stained hippocampus from patient 3 shows areas of neuron loss and astrogliosis (arrows) in images taken at increasing magnification (j-l).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      From: Fotheringham J, Akhyani N, Vortmeyer A, et al. Detection of active human herpesvirus-6 infection in the brain: Correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis 2007; 195:450. By permission of the Infectious Diseases Society of America. Copyright &copy; 2012 Oxford University Press.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23610=[""].join("\n");
var outline_f23_3_23610=null;
var title_f23_3_23611="Causes of scoliosis";
var content_f23_3_23611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of kyphoscoliosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neuromuscular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscular dystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poliomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vertebral disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteoporosis/osteomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pott's disease (tuberculous spondylitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurofibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of connective tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marfan's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehlers-Danlos syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morquio's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired abnormalities of the thoracic cage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracoplasty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23611=[""].join("\n");
var outline_f23_3_23611=null;
var title_f23_3_23612="Drug Rx arrhythmias WPW";
var content_f23_3_23612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical therapy of arrhythmias associated with Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Arrhythmia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Orthodromic",
"AV reentrant tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute termination*",
"       </td>",
"       <td>",
"        Vagal maneuvers",
"        <br/>",
"        IV verapamil",
"        <br/>",
"        IV adenosine",
"        <br/>",
"        <br/>",
"        <strong>",
"         Second-line:",
"        </strong>",
"        <br/>",
"        IV beta blocker",
"        <br/>",
"        IV digoxin",
"        <br/>",
"        IV amiodarone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic prevention&bull;",
"       </td>",
"       <td>",
"        Class IC",
"        <br/>",
"        <br/>",
"        <strong>",
"         Second-line:",
"        </strong>",
"        <br/>",
"        Beta blocker",
"        <br/>",
"        Calcium channel blocker",
"        <br/>",
"        Digoxin",
"        <br/>",
"        Class IA",
"        <br/>",
"        Amiodarone",
"        <br/>",
"        Sotalol",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antidromic AV reentrant",
"tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute termination*",
"       </td>",
"       <td>",
"        IV procainamide",
"       </td>",
"       <td>",
"        <strong>",
"         Consider only if diagnosis",
"secure:",
"        </strong>",
"        <br/>",
"        IV beta blocker",
"        <br/>",
"        IV calcium channel blocker",
"        <br/>",
"        IV digoxin",
"        <br/>",
"        IV adenosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic prevention&bull;",
"       </td>",
"       <td>",
"        Class IC",
"        <br/>",
"        <br/>",
"        <strong>",
"         Second-line:",
"        </strong>",
"        <br/>",
"        Class IA",
"        <br/>",
"        Amiodarone",
"       </td>",
"       <td>",
"        Beta blocker",
"        <br/>",
"        Calcium",
"channel blocker",
"        <br/>",
"        Digoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Atrial fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute termination*",
"       </td>",
"       <td colspan=\"2\">",
"        IV procainamide",
"        <br/>",
"        IV class IC if available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic prevention&bull;",
"       </td>",
"       <td colspan=\"2\">",
"        Class IC",
"        <br/>",
"        Class IA",
"        <br/>",
"        Amiodarone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Class IC: flecainide, propafenone; class IA: quinidine, procainamide, disopyramide.",
"     <br>",
"      * Cardioversion is indicated if hemodynamically unstable or drugs are ineffective.",
"      <br>",
"       &bull; Ablation of the accessory pathway is generally preferred to cure the arrhythmia.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23612=[""].join("\n");
var outline_f23_3_23612=null;
var title_f23_3_23613="Hallucinogen kinetics";
var content_f23_3_23613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacokinetic profile of common hallucinogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug/substance",
"      </td>",
"      <td class=\"subtitle1\">",
"       Typical dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Onset (min)*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Peak effect (hr)*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration of effects (hr)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2CB (4-bromo-2,5-dimethoxyphenethylamine)",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 10-40 mg",
"       </p>",
"       <p>",
"        Nasal: 5-10 mg",
"       </p>",
"      </td>",
"      <td>",
"       45-75",
"      </td>",
"      <td>",
"       4-6",
"      </td>",
"      <td>",
"       6-10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2CT-7 (2,5-dimethoxy-4-N-propylthiophenethylamine)",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 10-50 mg",
"       </p>",
"       <p>",
"        Nasal: 0.5-15 mg",
"       </p>",
"      </td>",
"      <td>",
"       60-120",
"      </td>",
"      <td>",
"       ND",
"      </td>",
"      <td>",
"       10-12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AMT (&alpha;-methyltryptamine)",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 20-40 mg",
"       </p>",
"       <p>",
"        Smoked: 6-10 mg",
"       </p>",
"      </td>",
"      <td>",
"       20-30",
"      </td>",
"      <td>",
"       4-8",
"      </td>",
"      <td>",
"       12-16",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DMT (dimethyltryptamine)",
"      </td>",
"      <td>",
"       IV, Smoked: 30-150 mg",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.5-1.5",
"      </td>",
"      <td>",
"       0.5-1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dextromethorphan",
"      </td>",
"      <td>",
"       Oral: 100-600 mg",
"      </td>",
"      <td>",
"       15-30",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       4-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5-MeO-DIPT (Foxy methoxy)",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 5-30 mg",
"       </p>",
"       <p>",
"        Nasal: 5-20 mg",
"       </p>",
"       <p>",
"        Smoked: 2-15 mg",
"       </p>",
"      </td>",
"      <td>",
"       20-60",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       3-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hawaiian baby woodrose (",
"       <em>",
"        Argyreia nervosa",
"       </em>",
"       )",
"      </td>",
"      <td>",
"       Oral: 5-10 seeds",
"      </td>",
"      <td>",
"       ND",
"      </td>",
"      <td>",
"       ND",
"      </td>",
"      <td>",
"       6-8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ibogaine",
"      </td>",
"      <td>",
"       Oral: 10 mg/kg",
"      </td>",
"      <td>",
"       2-4",
"      </td>",
"      <td>",
"       4-8",
"      </td>",
"      <td>",
"       18-24",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ketamine",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 200-300 mg",
"       </p>",
"       <p>",
"        IV: 50-100 mg",
"       </p>",
"       <p>",
"        IM: 75-125 mg",
"       </p>",
"       <p>",
"        Nasal: 60-250 mg",
"       </p>",
"      </td>",
"      <td>",
"       15-20",
"      </td>",
"      <td>",
"       0.5-1",
"      </td>",
"      <td>",
"       1.5-2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LSD (Lysergic acid diethylamide)",
"      </td>",
"      <td>",
"       Oral: 25-200 mcg",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       3-5",
"      </td>",
"      <td>",
"       4-12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mescaline (peyote)",
"      </td>",
"      <td>",
"       Oral: 200-500 mg (6-12 dried buttons)",
"      </td>",
"      <td>",
"       45-60",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Morning glory (",
"       <em>",
"        Ipomoea violacae",
"       </em>",
"       )",
"      </td>",
"      <td>",
"       Oral: 200-300 seeds",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       ND",
"      </td>",
"      <td>",
"       6-10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PCP (Phencyclidine)",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 2-6 mg",
"       </p>",
"       <p>",
"        IV, Nasal, Smoked: 1-3 mg",
"       </p>",
"      </td>",
"      <td>",
"       30-60",
"      </td>",
"      <td>",
"       1-4",
"      </td>",
"      <td>",
"       4-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psilocybin",
"      </td>",
"      <td>",
"       Oral: 10 mg (20-30 g fresh mushrooms; 1-2 g dried mushroom powder)",
"      </td>",
"      <td>",
"       20-30",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       4-6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Salvia divinorum",
"       </em>",
"      </td>",
"      <td>",
"       <p>",
"        Oral: 1 mg (5-10 leaves)",
"       </p>",
"       <p>",
"        Smoked: 200-500 mcg",
"       </p>",
"      </td>",
"      <td>",
"       5-15",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1-3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ND: no data available for this parameter.",
"     <br>",
"      * For",
"      <strong>",
"       oral",
"      </strong>",
"      doses. For most substances, peak levels following injection, nasal insufflation, or smoking occur within 1-5 minutes.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data for table adapted from:",
"     <br>",
"      Drug Enforcement Administration, US Department of Justice. Drugs and Chemicals of Concern, 2007. Available at file://www.deadiversion.usdoj.gov/drugs_concern. Last accessed September 19, 2008.",
"      <br>",
"       Nichols, DE. Hallucinogens. Pharmacol Ther 2004; 101:131.",
"       <br>",
"        The Vaults of Erowid. Available at file://www.erowid.org/psychoactives. Last accessed September 19, 2008.",
"        <br>",
"         Baselt, RC. Disposition of toxic drugs in man, seventh ed. Biomedical Publications, Foster City, CA, 2004.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23613=[""].join("\n");
var outline_f23_3_23613=null;
var title_f23_3_23614="Lone star tick PI";
var content_f23_3_23614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An adult female Amblyomma americanum (lone star tick)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 180px; height: 181px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23614=[""].join("\n");
var outline_f23_3_23614=null;
var title_f23_3_23615="Evaluation of 46 XX infant with virilization";
var content_f23_3_23615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of an infant with ambiguous genitalia and a 46,XX karyotype (SRY-negative)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 644px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SRY: sex-determining region on the Y chromosome; MIS: M&uuml;llerian inhibiting substance.",
"     <br/>",
"     * If SRY is positive in an infant with 46XX karyotype, this indicates SRY translocation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_3_23615=[""].join("\n");
var outline_f23_3_23615=null;
